Alnylam Pharmaceuticals (ALNY)

Feb 13, 2025, 5:01 PM EST - 9 days ago

Alnylam: Waiting For Regulatory Updates In March

Feb 13, 2025, 12:31 PM EST - 9 days ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:00 AM EST - 9 days ago

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Jan 30, 2025, 8:00 AM EST - 23 days ago

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Jan 12, 2025, 4:00 PM EST - 5 weeks ago

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Jan 7, 2025, 2:43 AM EST - 6 weeks ago

Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025

Jan 6, 2025, 8:00 AM EST - 6 weeks ago

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 3 months ago

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 3 months ago

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Nov 17, 2024, 9:30 AM EST - 3 months ago

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Nov 4, 2024, 8:00 AM EST - 3 months ago

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Oct 31, 2024, 11:26 AM EDT - 4 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Oct 30, 2024, 8:00 AM EDT - 4 months ago

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Oct 27, 2024, 9:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 17, 2024, 8:00 AM EDT - 4 months ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 4 months ago

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Oct 9, 2024, 7:00 AM EDT - 4 months ago

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Sep 29, 2024, 9:00 AM EDT - 5 months ago

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Sep 26, 2024, 8:00 AM EDT - 5 months ago

Alnylam to Webcast TTR Investor Day

Sep 12, 2024, 7:00 AM EDT - 5 months ago

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly

PFE

Aug 30, 2024, 5:18 PM EDT - 6 months ago

Steward Health Care and Medical Properties Trust Reach Settlement Agreement in Principle, Allowing for Steward-Operated Hospitals to Be Transitioned to New Ownership

Aug 30, 2024, 12:29 PM EDT - 6 months ago

Alnylam: HELIOS-B Success Priced In Already

Aug 30, 2024, 12:06 PM EDT - 6 months ago

Kern Subbasin Groundwater Sustainability Agencies Urge State to Consider Updated Plan

Aug 30, 2024, 9:51 AM EDT - 6 months ago

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Aug 30, 2024, 8:37 AM EDT - 6 months ago

Alnylam shares slide after heart drug data fails to impress investors

Aug 30, 2024, 6:00 AM EDT - 6 months ago

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Aug 28, 2024, 4:00 PM EDT - 6 months ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Aug 7, 2024, 8:00 AM EDT - 7 months ago

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

Aug 1, 2024, 1:58 PM EDT - 7 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:00 AM EDT - 7 months ago

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

Jul 18, 2024, 8:00 AM EDT - 7 months ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Jun 28, 2024, 7:00 AM EDT - 8 months ago

What's Next For Alnylam Stock After A 60% Rise In A Week?

Jun 24, 2024, 6:40 PM EDT - 8 months ago

Alnylam CEO on what is next for heart disease drug

Jun 24, 2024, 11:37 AM EDT - 8 months ago

HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster

Jun 24, 2024, 11:26 AM EDT - 8 months ago

Alnylam Stock Soars on Strong Results in Heart Drug Study

Jun 24, 2024, 11:03 AM EDT - 8 months ago

Alnylam Pharmaceuticals reports promising heart disease trial results

Jun 24, 2024, 10:52 AM EDT - 8 months ago

Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds

Jun 24, 2024, 10:22 AM EDT - 8 months ago

Cramer's Stop Trading: Alnylam Pharma

Jun 24, 2024, 9:49 AM EDT - 8 months ago

Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge

Jun 24, 2024, 9:12 AM EDT - 8 months ago

Alnylam's stock surges as heart drug vies with a Pfizer blockbuster

PFE

Jun 24, 2024, 8:30 AM EDT - 8 months ago

Alnylam Stock Soars After Positive Results From Heart Disease Study

Jun 24, 2024, 7:08 AM EDT - 8 months ago

Alnylam's heart disease drug meets main goal in late-stage study

Jun 24, 2024, 7:00 AM EDT - 8 months ago

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Jun 7, 2024, 6:26 PM EDT - 9 months ago

The 'Undercovered' Dozen From June 1-6

CLOV CRSP ENVX GAM HAL LPA PEO

Jun 3, 2024, 2:32 PM EDT - 9 months ago

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

May 7, 2024, 8:00 AM EDT - 10 months ago

Alnylam Issues 2023 Corporate Responsibility Report

May 2, 2024, 12:15 PM EDT - 10 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:00 AM EDT - 10 months ago

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Apr 30, 2024, 7:00 AM EDT - 10 months ago

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia